Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.50 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.42 |
| ▸ | WNT3A | P56704 | 5/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027482 | 0.86 | LDHA (0.49) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL5106786 | 0.86 | LDHA (0.49) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL5106595 | 0.78 | LDHA (0.53) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL5102869 | 0.75 | LDHA (0.50) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL4732176 | 0.73 | ALDH1A1 (0.54) | NPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL13327616 | 0.71 | RAB9A (0.48) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL18552087 | 0.71 | LDHA (0.47) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL15421297 | 0.71 | CYP11B1 (0.50) | LDHABAZ2BHPGDSCYP11B1CYP11B2 | |
| SCHEMBL18573165 | 0.70 | OXTR (0.56) | LDHABAZ2BHPGDSPTPN2PTPN1 | |
| SCHEMBL21480942 | 0.68 | FASN (0.47) | LDHABAZ2BHPGDSFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314882-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| WO-2006076598-A2 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154955-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154955-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | LDHA 4493/4885BAZ2B 2243/4885HPGDS 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.